110 related articles for article (PubMed ID: 12890147)
1. Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas.
Kuittinen O; Apaja-Sarkkinen M; Turpeenniemi-Hujanen T
Eur J Haematol; 2003 Aug; 71(2):91-9. PubMed ID: 12890147
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma.
Citak EC; Oguz A; Karadeniz C; Akyurek N
Pathol Res Pract; 2008; 204(2):89-96. PubMed ID: 18207652
[TBL] [Abstract][Full Text] [Related]
3. Role of gelatinases (MMP-2 and MMP-9), TIMP-1, vascular endothelial growth factor (VEGF), and microvessel density on the clinicopathological behavior of childhood non-Hodgkin lymphoma.
Citak EC; Oguz A; Karadeniz C; Akyurek N
Pediatr Hematol Oncol; 2008; 25(1):55-66. PubMed ID: 18231955
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas.
Kossakowska AE; Edwards DR; Prusinkiewicz C; Zhang MC; Guo D; Urbanski SJ; Grogan T; Marquez LA; Janowska-Wieczorek A
Blood; 1999 Sep; 94(6):2080-9. PubMed ID: 10477738
[TBL] [Abstract][Full Text] [Related]
5. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma.
Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2002 Oct; 69(4):205-12. PubMed ID: 12431239
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome.
Ara T; Fukuzawa M; Kusafuka T; Komoto Y; Oue T; Inoue M; Okada A
J Pediatr Surg; 1998 Aug; 33(8):1272-8. PubMed ID: 9722003
[TBL] [Abstract][Full Text] [Related]
9. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
10. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
[TBL] [Abstract][Full Text] [Related]
11. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
12. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma.
Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Oncology; 2005; 68(2-3):196-203. PubMed ID: 16006757
[TBL] [Abstract][Full Text] [Related]
13. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
Guo W; Chen G; Zhu C; Wang H
Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
15. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion.
Stearns ME; Rhim J; Wang M
Clin Cancer Res; 1999 Jan; 5(1):189-96. PubMed ID: 9918218
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma.
Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2004 Jan; 72(1):1-9. PubMed ID: 14962256
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
19. Role of matrix metalloproteinase MMP-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP-1) in the clinical progression of pediatric acute lymphoblastic leukemia.
Saleh M; Khalil M; Abdellateif MS; Ebeid E; Madney Y; Kandeel EZ
Hematology; 2021 Dec; 26(1):758-768. PubMed ID: 34555302
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
